TradeFlare's AI research teams analysed JAZZ on 15 market nights between February 25, 2026 and August 7, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 7, 2026 | BUY | $256.65 | $300.00 / $230.99 | -4.5% | -3.8% | The current market regime is bullish, and the technical setup suggests an imminent breakout. |
| August 6, 2026 | BUY Published signal · closed after 45 days -6.2% |
$261.57 | $300.00 / $235.70 | -4.2% | -3.5% | The fundamental and sentiment tailwinds suggest a sustained upward move, but technicals near resistance warrant a medium-term outlook. |
| August 3, 2026 | BUY | $252.86 | $280.50 / $229.50 | +2.0% | -0.4% | The fundamental and sentiment teams are bullish, suggesting potential for upside over a medium-term horizon. |
| July 31, 2026 | BUY | $258.38 | — / — | +1.5% | -3.3% | The market regime is neutral, and while the technicals are bullish, the fundamental and sentiment teams are neutral, and the risk score is high. |
| July 30, 2026 | BUY | $255.97 | $286.63 / $217.58 | -0.7% | -2.8% | The technical setup suggests a short-term move to resistance, supported by fundamental strength. |
| July 29, 2026 | BUY | $256.92 | — / — | +2.2% | -2.6% | The current technical setup at resistance and mixed fundamental signals warrant a cautious approach. |
| July 28, 2026 | BUY | $255.43 | $290.00 / $233.31 | +1.8% | +1.3% | The fundamental and sentiment teams are bullish, suggesting a medium-term upward trend is likely. |
| July 23, 2026 | BUY | $250.41 | — / — | +1.4% | -2.4% | Strong revenue growth driven by key products in neuroscience and oncology. |
| July 22, 2026 | BUY | $254.22 | — / — | +2.2% | +0.7% | The current market conditions and the stock's technical setup do not present a clear, high-conviction trading opportunity. |
| July 21, 2026 | BUY | $243.47 | — / — | +1.1% | -0.5% | The market regime is neutral, and the stock's directional teams are not bullish enough to warrant a buy. |
| June 26, 2026 | HOLD | $226.20 | — / — | +6.2% | +11.1% | Positive analyst outlook and pipeline growth. |
| June 23, 2026 | BUY | $225.92 | — / — | +4.7% | +8.8% | Continued positive clinical trial data for key pipeline drugs. |
| May 25, 2026 | BUY | $239.83 | $295.80 / $203.85 | -4.8% | -3.2% | The stock is in a strong uptrend with positive analyst sentiment, suggesting a medium-term upward move. |
| May 7, 2026 | BUY | $228.57 | $250.00 / $211.43 | +1.8% | +5.1% | The stock is breaking out of a 52-week high with strong momentum, suggesting a continuation of the uptrend over several weeks. |
| February 25, 2026 | BUY | — | $216.83 / $166.37 | -4.1% | -3.9% |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.